Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine PR 48 mg once daily vs Betahistine IR 24 mg twice daily in Menière's disease
2024-518347-38-00Phase 3Authorised
- Sponsor
- Intas Pharmaceuticals
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of betahistine in Meniere Disease (2 arms), sponsored by Intas Pharmaceuticals. Primary endpoints: Percentage of significant responders (GISFaV-based) and Change in vertigo disturbance stage by GISFaV items. Planned start Oct 2024; status: authorised.
02
Drugs
betahistine
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on 2024-518347-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518347-38-00.